Literature DB >> 30183397

Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.

James M Falko.   

Abstract

OBJECTIVE: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in lipoprotein lipase, resulting in accumulation of chylomicrons in plasma and hypertriglyceridemia. Elevated triglycerides cause several complications in patients, the most serious being episodes of acute pancreatitis. This review focuses on expert guidance and opinion from an experienced lipidologist and endocrinologist as well as a current review of the literature, as there are no specific guidelines on FCS.
METHODS: Discussion of expert guidance and opinion review of current literature.
RESULTS: To date, there is no pharmacologic treatment for affected patients, and management options primarily include adoption of an extremely restricted, very-low-fat diet, along with avoidance of certain medications and alcohol. Endocrinologists often diagnose and manage patients with metabolic disorders, including patients with high triglyceride levels, but rare diseases like FCS can be missed or poorly evaluated due to knowledge gaps about disease state. Given endocrinologists' role in the treatment of lipid disorders, it is important that they understand the clinical signs and symptoms of FCS to correctly diagnose patients. Patients with FCS can be identified based on a defined clinical criteria and a thorough review of medical history, after excluding differential diagnoses and secondary factors. Typical manifestations include hypertriglyceridemia characterized by lipemic serum, history of abdominal pain, and acute/recurrent pancreatitis. Secondary factors to be excluded are pregnancy, alcohol abuse, uncontrolled diabetes, and use of certain medications.
CONCLUSION: FCS is a rare, inherited lipid disorder disease that often goes underdiagnosed and unmanaged. This review provides a summary of clinical characteristics of FCS that can be potentially used to screen patients in an endocrinologist's office and direct them to the appropriate standard of care. ABBREVIATIONS: apoB = apolipoprotein B; apoC-III = apolipoprotein CIII; ASO = antisense oligonucleotide; FCS = familial chylomicronemia syndrome; HTG = hypertriglyceridemia; LPL = lipoprotein lipase; LPLD = lipoprotein lipase deficiency.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30183397     DOI: 10.4158/EP-2018-0157

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  11 in total

Review 1.  Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.

Authors:  Patricia Hernandez; Neena Passi; Taher Modarressi; Vivek Kulkarni; Meshal Soni; Fran Burke; Archna Bajaj; Daniel Soffer
Journal:  Curr Atheroscler Rep       Date:  2021-09-13       Impact factor: 5.113

2.  Abdominal Pain as the Manifestation of Chylomicronemia Syndrome During Pregnancy: A Challenging Diagnosis.

Authors:  Catarina Parente; Rúben Reis; Manuel Toscano; Isabel Botelho; Armindo Ramos
Journal:  Cureus       Date:  2021-04-06

Review 3.  Causes and Consequences of Hypertriglyceridemia.

Authors:  Chris J Packard; Jan Boren; Marja-Riitta Taskinen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-14       Impact factor: 5.555

4.  Familial chylomicronemia syndrome: a case report.

Authors:  Ammu Thampi Susheela; Padmesh Vadakapet; Lekshmi Pillai; Susheela Thampi
Journal:  J Med Case Rep       Date:  2021-01-08

5.  Case Report: Successful Management of a 29-Day-Old Infant With Severe Hyperlipidemia From a Novel Homozygous Variant of GPIHBP1 Gene.

Authors:  Shu Liu; Zhiqing Wang; Xianhua Zheng; Ye Zhang; Sisi Wei; Haimei OuYang; Jinqun Liang; Nuan Chen; Weihong Zeng; Jianhui Jiang
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

Review 6.  Ten things to know about ten cardiovascular disease risk factors.

Authors:  Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2021-01-23

7.  Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report.

Authors:  Min-Huan Lin; Xiao-Hui Tian; Xiu-Lan Hao; Hui Fei; Jian-Lan Yin; Dan-Dan Yan; Tian Li
Journal:  BMC Pregnancy Childbirth       Date:  2020-05-06       Impact factor: 3.007

8.  The burden of familial chylomicronemia syndrome in Canadian patients.

Authors:  Daniel Gaudet; Michael Stevenson; Nelly Komari; Grace Trentin; Caroline Crowson; Nandini Hadker; Sophie Bernard
Journal:  Lipids Health Dis       Date:  2020-06-02       Impact factor: 3.876

9.  Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP).

Authors:  Shabnam Dildar; Tahir Sultan Shamsi
Journal:  BMC Endocr Disord       Date:  2020-02-11       Impact factor: 2.763

10.  Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.

Authors:  Chie Iitake; Daisaku Masuda; Masahiro Koseki; Shizuya Yamashita
Journal:  Cardiovasc Diabetol       Date:  2020-11-27       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.